Champions Oncology, Inc. reported its financial results for the quarter ending July 31, 2025, revealing a slight decline in revenue and a net loss compared to the same period last year. The company generated oncology revenue of $13.995 million, a decrease of 0.5% from $14.061 million in the prior year. The net loss attributable to common shareholders was $436,000, or $(0.03) per share, contrasting with a net income of $1.313 million, or $0.10 per share, for the same quarter in 2024. The decline in profitability was attributed to increased operating expenses, particularly in research and development and the cost of oncology revenue.
Total operating expenses for the quarter rose to $14.522 million, up 14.1% from $12.732 million in the previous year. The cost of oncology revenue increased by 13.1% to $7.995 million, primarily due to higher outsourced lab services. Research and development expenses surged by 43.2% to $2.082 million, reflecting increased investment in the company’s data licensing platform and its subsidiary, Corellia. Sales and marketing expenses also rose by 10.5% to $1.855 million, driven by compensation costs associated with the growth of the data license business.
Champions Oncology's balance sheet as of July 31, 2025, showed total assets of $30.546 million, down from $32.344 million at the end of April 2025. Current liabilities decreased slightly to $22.698 million from $23.853 million, while total liabilities were reported at $27.008 million, down from $28.572 million. The company’s cash and cash equivalents increased to $10.325 million from $9.785 million, indicating a positive cash flow from operations of approximately $600,000 for the quarter.
The company continues to focus on its TumorGraft Technology Platform, which aims to personalize cancer care through predictive studies of drug efficacy. Despite the challenges faced in the current fiscal period, management believes that the existing cash reserves, along with anticipated cash flows from operations, will be sufficient to fund operations for at least the next twelve months. However, the company acknowledged the potential need for additional capital in the future, which may not be guaranteed under favorable terms.
Looking ahead, Champions Oncology is committed to enhancing its research capabilities and expanding its service offerings. The company is actively evaluating strategic options to maximize value from its drug discovery business, which may include potential spin-out transactions or capital raises. The management remains optimistic about the long-term prospects of its oncology services and technology solutions, despite the current financial challenges.
About CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a technology-driven oncology research company specializing in drug discovery and development. It operates a proprietary bank of approximately 1,500 Patient Derived Xenograft (PDX) tumor models used in advanced in vivo and ex vivo pharmacology platforms. Serving pharmaceutical and biotechnology companies globally, Champions offers research services, data licensing, and bioinformatics SaaS tools to accelerate cancer drug development through integrated computational and experimental platforms.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.